Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

NCT03066739 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT03066739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Terminated
Start date
February 25, 2023
Completion date
December 1, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperalgesia